Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure

Neoplasia

Volumn 9, Issue 2, 2007, Pages 108-112

  Ley, Carsten D ^a,c   Horsmany, Michael R ^b   Kristjansen, Paul E G ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Combretastatin A4 disodium phosphate; Interstitial fluid pressure; Perfusion; Vascular damaging agent; Wick in needle

Indexed keywords

COMBRETASTATIN A4 PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; BREAST CARCINOMA; CARCINOMA CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; LASER DOPPLER FLOWMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TISSUE PRESSURE; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION;

EID: 33847322988     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06733     Document Type: Article

References (34)

1. Pettit GR, Singh SB, Niven ML, Hamel E, and Schmidt JM (1987). Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 50, 119-131.
2. Chaplin DJ and Dougherty GJ (1999). Tumour vasculature as a target for cancer therapy. Br J Cancer 80 (1), 57-64.
3. Lin CM, Singh SB, Chu PS, Dempcy RO, Schmidt JM, Pettit GR, and Hamel E (1988). Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol 34, 200-208.
4. Pettit GR, Temple C, Narayanan VL, Varma R, Simpson MJ, Boyd MR, Rener GA, and Bansal N (1995). Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 10, 299-309.
5. Chaplin DJ (2003). Drug based approaches for targeting tumor vasculature: development of combretastatin A4 phosphate. Pathophysiol Haemost Thromb 33 (1), 9-10.
6. el Zayat AA, Degen D, Drabek S, Clark GM, Pettit GR, and Von Hoff DD (1993). In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub). Anticancer Drugs 4, 19-25.
7. Nabha SM, Wall NR, Mohammad RM, Pettit GR, and Al Katib AM (2000). Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines. Anticancer Drugs 11, 385-392.
8. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, and Chaplin DJ (1997). Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57, 1829-1834.
9. Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, and Tozer GM (2001). Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 21, 93-102.
10. Iyer S, Chaplin DJ, Rosenthal DS, Boulares AH, Li LY, and Smulson ME (1998). Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res 58, 4510-4514.
11. Chaplin DJ, Pettit GR, and Hill SA (1999). Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 19, 189-195.
12. Tozer GM, Kanthou C, and Baguley BC (2005). Disrupting tumour blood vessels. Nat Rev Cancer 5, 423-435.
13. Kanthou C and Tozer GM (2002). The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99, 2060-2069.
14. Grosios K, Holwell SE, McGown AT, Pettit GR, and Bibby MC (1999). In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81, 1318-1327.
15. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, Barber PR, Vojnovic B, and Chaplin DJ (2001). Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61, 6413-6422.
16. Parkins CS, Holder AL, Hill SA, Chaplin DJ, and Tozer GM (2000). Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br J Cancer 83, 811-816.
17. Brooks AC, Kanthou C, Cook IH, Tozer GM, Barber PR, Vojnovic B, Nash GB, and Parkins CS (2003). The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro. Anticancer Res 23, 3199-3206.
18. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, and Chaplin DJ (1999). Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59, 1626-1634.
19. Beauregard DA, Hill SA, Chaplin DJ, and Brindle KM (2001). The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 61, 6811-6815.
20. Tozer GM, Kanthou C, Parkins CS, and Hill SA (2002). The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 83, 21-38.
21. Kristjansen PE, Kragh M, Murata R, Quistorff B, and Horsman MR (2001). Early changes in vascular physiology of solid tumors following combretastatin A-4 disodium phosphate treatment. Abstract presented at 2001 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
22. Eikesdal HP, Landuyt W, and Dahl O (2002). The influence of combretastatin A-4 and vinblastine on interstitial fluid pressure in BT4An rat gliomas. Cancer Lett 178, 209-217.
23. Zhao D, Jiang L, Hahn EW, and Mason RP (2005). Tumor physiologic response to combretastatin A4 phosphate assessed by MRI. Int J Radiat Oncol Biol Phys 62, 872-880.
24. Kragh M, Quistorff B, Horsman MR, and Kristjansen PE (2002). Acute effects of vascular modifying agents in solid tumors assessed by non-invasive laser Doppler flowmetry and near infrared spectroscopy. Neoplasia 4, 263-267.
25. Murata R, Siemann DW, Overgaard J, and Horsman MR (2001). Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 60, 155-161.
26. Murata R, Overgaard J, and Horsman MR (2001). Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 77, 195-204.
27. Kragh M, Quistorff B, and Kristjansen PE (2001). Quantitative estimates of angiogenic and anti-angiogenic activity by laser Doppler flowmetry (LDF) and near infra-red spectroscopy (NIRS). Eur J Cancer 37, 924-929.
28. Overgaard J (1980). Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int J Radiat Oncol Biol Phys 6, 1507-1517.
29. Murata R, Overgaard J, and Horsman MR (2001). Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys 51, 1018-1024.
30. Fadnes HO, Reed RK, and Aukland K (1977). Interstitial fluid pressure in rats measured with a modified wick technique. Microvasc Res 14, 27-36.
31. Boucher Y and Jain RK (1992). Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 52, 5110-5114.
32. Eikesdal HP, Schem BC, Mella O, and Dahl O (2000). The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. Int J Radiat Oncol Biol Phys 46, 645-652.
33. Eikesdal HP, Bjerkvig R, Mella O, and Dahl O (2001). Combretastatin A-4 and hyperthermia; a potent combination for the treatment of solid tumors. Radiother Oncol 60, 147-154.
34. Hori K and Saito S (2003). Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer 89, 1334-1344.